Amgen's decision reverberated beyond the 48 patients in the trials because the drug, called glial cell line-derived neurotrophic factor, or GDNF, had the potential to stall or even reverse the progression of the disease rather than just reduce the symptoms, as the currently available Parkinson's drugs do.
Their willingness also raises an ethical question: If a company stops developing a drug for safety or efficacy reasons, is it obligated to continue supplying it to patients from its clinical trials?
Japanese researchers said Tuesday they had successfully treated monkeys with Parkinson's disease through a stem cell transplant, potentially paving the way
